消渴灵联合格列齐特治疗2型糖尿病的临床效果研究
详细信息 查看官网全文
- 论文作者：成殷勤 ; 陈红梅 ; 何峰 ; 李洪彬
- 年：2016
- 作者机构：江苏省南通市第二人民医院内分泌科;
- 论文关键词：消渴灵 ; 格列齐特 ; 2型糖尿病
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R587.1
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：2
- 文件大小：2064k
- 原文格式：D
- 会议级别：全国
摘要
目的:探讨消渴灵联合格列齐特治疗2型糖尿病的临床效果。方法:选取来我院就诊的2型糖尿病患者80例,利用随机数字表法随机分为对照组和治疗组,每组各40例,对照组给予口服格列齐特缓释片治疗,治疗组在对照组的基础上给予消渴灵颗粒,疗程均为12周。测定患者治疗前后的空腹血糖、空腹胰岛素、餐后小时血糖、糖化血红蛋白,计算胰岛素抵抗指数以及胰岛素β细胞功能指数来评价两组的治疗效果。结果:治疗后比较两组患者FPG、2h FG、Hb A1c的数值,可以看出治疗组效果明显好于对照组,说明治疗组得到了较好的治疗效果,差异具统计学差异(P<0.05)。治疗后可以看到FINS、HOMA-IR的数值较治疗前有明显下降,HOMA-β明显上升,两组患者结果治疗后有差异,差异具统计学差异(P<0.05)。治疗组临床总有效率为95.00%,对照组则为82.50%,治疗组临床总有效率显著优于对照组(P<0.01)。结论:消渴灵治疗2型糖尿病有很好的效果,和格列齐特联用效果更好,并且可以促进胰岛β细胞的功能恢复以及减弱胰岛素抵抗。
引文
[1]Zhu W W,Yang H X.Diagnosis of Gestational Diabetes Mellitus in China[J].Diabetes Care,2013,36(10):230-234.
[2]Shi R,Lei Y M,Song D P,et al.Detecting of Mitochondrial t RN~(ALeu(UUR))Mutations at Position A3243G in Patients with Type 2 Diabetes Mellitus in Yunnan[J].Journal of Kunming Medical University,2014,10(12):231-234.
[3]Khazrai Y M,Defeudis G,Pozzilli P.Effect of diet on type 2 diabetes mellitus:a review.[J].Diabetes/metabolism Research&Reviews,2014,30(S1):24-33.
[4]Geloneze B,Vasques A C J,Stabe C F C,et al.HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome:Brazilian Metabolic Syndrome Study(BRAMS).[J].Arq.bras.endocrinol.metab,2009,53(2):281-287.
[5]Simental-Mendía L E,Casta.eda-Chacón A,Rodriguez-Morán M,et al.Relationship between elevated triglyceride levels with the increase of HOMA-IR and HOMA-βin healthy children and adolescents with normal weight[J].European Journal of Pediatrics,2015,174(5):597-605.
[6]Shibasaki S,Imagawa A,Hanafusa T.Fulminant Type 1 Diabetes Mellitus[J].Advances in Experimental Medicine&Biology,2013,23(21):321-324.
[7]Lernmark A,Larsson H E.Immune therapy in type 1 diabetes mellitus.[J].Nature Reviews Endocrinology,2013,9(2):92-103.
[8]Lee Y C,Lee W J,Liew P L.Predictors of remission of type 2 diabetes mellitus in obese patients after gastrointestinal surgery.[J].Obesity Research&Clinical Practice,2013,7(6):e494-e500.
[9]Jiang W,Yue L,Sun H.Therapeutic Effect and Safety of Repaglinide and Gliclazide in the Treatment of Elderly Type 2 Diabetes Mellitus[J].China Pharmacist,2014,11(12):452-455.
[10]Tan F,Li H,Ma M,et al.Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats.[J].Brain Research,2014,1560(18):83–90.
[11]赵丽华,宫文良.消渴脂平治疗糖尿病合并高脂血症(痰瘀壅阻证)的临床研究[J].中国医药指南,2012,(36):283-284.
[12]张成义,陈曦,李贺,等.消渴灵冲剂降糖作用的研究[J].北华大学学报:自然科学版,2007,8(2):154-156.
[13]穆秋山.消渴灵治疗2型糖尿病40例疗效观察[J].山东中医杂志,2006,24(10):595-597.
[14]曾江正,董克礼,李良明,等.消渴灵方治疗2型糖尿病周围神经病变的临床观察[J].湖南中医药大学学报,2004,24(4):46-48.
[2]Shi R,Lei Y M,Song D P,et al.Detecting of Mitochondrial t RN~(ALeu(UUR))Mutations at Position A3243G in Patients with Type 2 Diabetes Mellitus in Yunnan[J].Journal of Kunming Medical University,2014,10(12):231-234.
[3]Khazrai Y M,Defeudis G,Pozzilli P.Effect of diet on type 2 diabetes mellitus:a review.[J].Diabetes/metabolism Research&Reviews,2014,30(S1):24-33.
[4]Geloneze B,Vasques A C J,Stabe C F C,et al.HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome:Brazilian Metabolic Syndrome Study(BRAMS).[J].Arq.bras.endocrinol.metab,2009,53(2):281-287.
[5]Simental-Mendía L E,Casta.eda-Chacón A,Rodriguez-Morán M,et al.Relationship between elevated triglyceride levels with the increase of HOMA-IR and HOMA-βin healthy children and adolescents with normal weight[J].European Journal of Pediatrics,2015,174(5):597-605.
[6]Shibasaki S,Imagawa A,Hanafusa T.Fulminant Type 1 Diabetes Mellitus[J].Advances in Experimental Medicine&Biology,2013,23(21):321-324.
[7]Lernmark A,Larsson H E.Immune therapy in type 1 diabetes mellitus.[J].Nature Reviews Endocrinology,2013,9(2):92-103.
[8]Lee Y C,Lee W J,Liew P L.Predictors of remission of type 2 diabetes mellitus in obese patients after gastrointestinal surgery.[J].Obesity Research&Clinical Practice,2013,7(6):e494-e500.
[9]Jiang W,Yue L,Sun H.Therapeutic Effect and Safety of Repaglinide and Gliclazide in the Treatment of Elderly Type 2 Diabetes Mellitus[J].China Pharmacist,2014,11(12):452-455.
[10]Tan F,Li H,Ma M,et al.Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats.[J].Brain Research,2014,1560(18):83–90.
[11]赵丽华,宫文良.消渴脂平治疗糖尿病合并高脂血症(痰瘀壅阻证)的临床研究[J].中国医药指南,2012,(36):283-284.
[12]张成义,陈曦,李贺,等.消渴灵冲剂降糖作用的研究[J].北华大学学报:自然科学版,2007,8(2):154-156.
[13]穆秋山.消渴灵治疗2型糖尿病40例疗效观察[J].山东中医杂志,2006,24(10):595-597.
[14]曾江正,董克礼,李良明,等.消渴灵方治疗2型糖尿病周围神经病变的临床观察[J].湖南中医药大学学报,2004,24(4):46-48.